Recursion Pharmaceuticals: Unprecedented Scale

To address this issue, companies like Recursion are trying to identify failures early on and accelerate pre-clinical development of high potential drug candidates. While there is likely significant value just in improving the productivity of pre-clinical research, late-stage clinical failures are the primary driver of costs in today's pharmaceutical R&D model, making improving clinical success rates critical to improving the return on R&D spend. Recursion believes that the development and convergence of a r ...